Polyamine metabolism as target for cancer chemoprevention (Review)

International Journal of Oncology

Volumn 13, Issue 5, 1998, Pages 993-1006

  Seiler, Nikolaus ^a,b   Atanassov, Christo L ^a   Raul, Francis ^a  

^a INSERM   (France)

^b IRCAD   (France)

Author keywords

Chemoprevention; Metabolism; Polyamine

Indexed keywords

1 ETHYNYL 4 METHYL 1,4 BUTANEDIAMINE; 4 AMIDINO 1 INDANONE 2' AMIDINOHYDRAZONE; 5' [(4 AMINO 2 BUTENYL)METHYLAMINO] 5' DEOXYADENOSINE; ANTINEOPLASTIC AGENT; CALMODULIN INHIBITOR; CURCUMIN; EFLORNITHINE; MITOGUAZONE; N1 ETHYL N11 CYCLOHEPTYLNORSPERMINE; N1,N11 DIETHYLNORSPERMINE; POLYAMINE; POLYAMINE DERIVATIVE; PUTRESCINE; RETINOID; SPERMIDINE; SPERMINE; SPERMINE DERIVATIVE; UNCLASSIFIED DRUG;

CANCER PREVENTION; CELL TRANSFORMATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON CARCINOGENESIS; DOSE CALCULATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INDUCTION; ENZYME REPRESSION; GASTROINTESTINAL TRACT; GENE OVEREXPRESSION; HUMAN; MALIGNANT TRANSFORMATION; METABOLIC INHIBITION; ORAL DRUG ADMINISTRATION; OTOTOXICITY; POLYAMINE SYNTHESIS; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS; TUMOR PROMOTION;

EID: 0031733015     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.5.993     Document Type: Review

References (202)

1. Krishnan K and Brenner DE: Chemoprevention for colorectal cancer. Gastroenterol Clin North Am 25: 821-858, 1996.
2. Hong WK and Sporn MB: Recent advances in chemoprevention of cancer. Science 278: 1073-1077, 1997.
3. Kahn MJ and Morrison DG: Chemoprevention for colorectal carcinoma. Hematol Oncol Clin North Am 11: 779-794, 1997.
4. Montoya RG and Wargovich MJ: Chemoprevention of gastrointestinal cancer. Cancer Metastasis Rev 16: 405-419, 1997.
5. Wattenberg LW: An overview of chemoprevention: current status and future prospects. Proc Soc Exp Biol Med 216: 133-141, 1997.
6. Stoner GD, Morse MA and Kelloff GJ: Perspectives in cancer chemoprevention. Environ Health Perspect 105 (Suppl. 4): 945-954, 1997.
7. Siegfried JM: Biology and chemoprevention of lung cancer. Chest 113 (Suppl. 1): 40S-45S, 1998.
8. Vogelstein B and Kinzler KW: The multistep nature of cancer. Trends Genet 9: 138-141, 1993.
9. Bey P: Substrate-induced irreversible inhibition of α-aminoacid dccarboxylases. Application to glutamate, aromatic L-α-aminoacid and ornithine decarboxylase. In: Enzyme-Activated Irreversible Inhibitors. Seiler N, Jung MJ and Koch-Weser J (eds). Eisevier/ North Holland, Amsterdam, pp27-41, 1978.
10. Kadmon D: Chemoprevention in prostate cancer: the role of difluoromethylornithine. J Cell Biochem 16H (Suppl.): 122-127, 1992.
11. Meyskens FL and Gerner EW: Development of difluoromethylornithine as a chemoprevention agent for the management of colon cancer. J Cell Biochem 22 (Suppl.): 126-131, 1995.
12. Pegg AE, Shantz LM and Coleman CS: Ornithine decarboxylase as a target for chemoprevention. J Cell Biochem 22 (Suppl.): 132-138, 1995.
13. Berchtold CM, Kensler TW and Casero RA Jr: The polyamine metabolic pathway as a target for chemoprevention. In: Polyamines: Regulation and Molecular Interaction. Casero RA Jr (ed). Springer/Landes, New York, Austin, pp205-231, 1995.
14. Pegg AE: Recent advances in the biochemistry of polyamines in eukaryotes. Biochem J 234: 249-262, 1988.
15. Bachrach U and Hcimer YM (eds): The Physiology of Polyamines. Vol. 1. CRC Press, Boca Raton, 1-355, 1989.
16. Jänne J, Alhonen L and Leinonen P: Polyamines: from molecular biology to clinical applications. Ann Med 23: 241-259, 1991.
17. Moulinoux JP and Quemener V (eds): Les Polyamines. Flammarion, Paris, 1991.
18. Seiler N: Pharmacological properties of the natural polyamines and their depletion by biosynthesis inhibitors as a therapeutic approach. In: Progress in Drug Research. Vol. 37. Jucker E (ed). Birkhäuser, Basel, pp107-159, 1991.
19. Seiler N: Formation, catabolism and properties of the natural polyamines. In: The Neuropharmacology of Polyamines. Carter C (ed). Academic Press, London, pp1-36, 1994.
20. Marton LJ and Pegg AE: Polyamines as targets for therapeutic intervention. Annu Rev Pharmacol Toxicol 35: 55-91, 1995.
21. Persson L, Svensson F and Loevkvist-Wallstroem E: Regulation of polyamine metabolism. In: Polyamines in Cancer: Basic Mechanisms and Clinical Approaches. Nishioka K (ed). Springer/ Landes, New York, Austin, pp19-43, 1996.
22. Cohen SS: A Guide to the Polyamines. Oxford University Press, New York, 595 pages, 1998.
23. Seiler N, Bolkenius FN and Rennert OM: Interconversion, catabolism and elimination of the polyamines. Med Biol 59: 334-346, 1981.
24. Seiler N, Delcros JG and Moulinoux JP: Polyamine transport in mammalian cells. An update. Int J Biochem Cell Biol 28: 843-861, 1996.
25. Robinson-White A, Baylin SB, Olivecrona T and Beaven MA: Binding of diamine oxidase activity to rat and guinea pig microvascular endothelial cells. Comparisons with lipoprotein lipase binding. J Clin Invest 76: 983-100, 1985.
26. Bardocz S, Duguid TJ, Brown DS, Grant G, Pusztai A, White A and Ralph A: The importance of dietary polyamines in cell regeneration and growth. Br J Nutr 73: 819-828, 1995.
27. Kusche J, Mennigen R, Leisten L and Elbers A: Large bowel tumor promotion by inhibition of mucosal diamine oxidase in rats I. Morphological aspects. Biogenic Amines 6: 15-26, 1989.
28. G-nitro-L-arginine, and aminoguanidine on constitutive and inducible nitric oxide synthase in rat aorta. Biochem Biophys Res Commun 199: 147-154, 1994.
29. Paulsen JE, Reistad R, Eliassen KA, Sjaastad OV and Alexander J: Dietary polyamines promote the growth of azoxymethane-induced aberrant crypt foci in rat colon. Carcinogenesis 18: 1871-1875, 1997.
30. Bird RP: Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 93: 55-71, 1995.
31. Duranton B, Nsi-Emvo E, Schleiffer R, Gossé F, Galluser M and Raul F: Suppression of preneoplastic changes in the intestine of rats fed low levels of polyamines. Cancer Res 57: 573-575, 1997.
32. Ohmori T, Okada K, Tabei R and Shibata T: Effects on tumor induction, growth, metastasis and histology of concurrent administration of putrescine and its metabolizing inhibitor α-difluoromethylornithine in nickel tumorigenesis in soft (issue. Carcinogenesis 15: 647-652, 1994.
33. Wang W, Liu LQ and Higuchi CM: Mucosal polyamine measurements and colorectal cancer risk. J Cell Biochem 63: 252-257, 1993.
34. McCann PP and Pegg AE: Ornithine decarboxylase as an enzyme target for therapy. Pharmacol Ther 54: 195-215, 1992.
35. Kim YJ, Pan H and Verma AK: Non-AP-1 tumor promoter 12-O-tetradecanoylphorbol-13-acetate-responsive sequences in the human ornithine decarboxylase gene. Mol Carcinogen 10: 169-179, 1994.
36. Kitchin KT, Brown JL and Kulkarni AP: Complementarity of genotoxic and non-genotoxic predictors of rodent carcinogenicity. Teratogen Carcinog Mutagen 13: 83-100, 1994.
37. Bachrach U: Polyamines and neoplastic transformation. In: Polyamines in Cancer: Basic Mechanisms and Clinical Approaches. Nishioka K (ed). Springer/Landes, New York, Austin, pp45-74, 1996.
38. Celano P, Berchtold CM, Giardello FM and Casero RA Jr: Modulation of growth gene expression by selective alteration of polyamines in human colon carcinoma cells. Biochem Biophys Res Commun 165: 384-390, 1989.
39. Bello-Fernandez C, Packham G and Cleveland JL: The ornithine decarboxylase gene is a transcriptional target of c-myc. Proc Natl Acad Sci USA 90: 7804-7808, 1993.
40. Wagner AJ, Meyers C, Laimins LA and Hay N: c-myc induces the expression and activity of ornithine decarboxylase. Cell Growth Differ 4: 879-883, 1993.
41. Hurta RAR and Wright JA: Ornithine decarboxylase gene expression is aberrantly regulated via the cAMP signal transduction pathway in malignant H-ras transfected cell lines. J Cell Physiol 161: 383-391, 1994.
42. Wrighton C and Busslinger M: Direct transcriptional stimulation of the ornithine decarboxylase gene byfos in PC12 cells, but not in fibroblasts. Mol Cell Biol 13: 4657-4669, 1993.
43. Tabib A and Bachrach U: Activation of the proto-oncogene c-myc and c-fos by c-ras. Involvement of polyamines. Biochem Biophys Res Commun 202: 720-727, 1994.
44. Auvinen M, Paasinen A, Andersson LC and Hölttä E: Ornithine decarboxylase activity is critical for cell transformation. Nature 360: 355-358, 1992.
45. Moshier JS, Dosescu J, Skunca M and Luk GD: Transformation of NIH/3T3 cells by ornithine decarboxylase overexpression. Cancer Res 53: 2618-2622, 1993.
46. Auvinen M: Cell transformation, invasion, and angiogenesis: a regulatory role for ornithine decarboxylase and polyamines. J Natl Cancer Inst 89: 533-537, 1997.
47. Auvinen M, Laine A, Paasinen-Sohns A, Kangas A, Kangas L, Saksela O, Andersson LC and Hölttä E: Human ornithine decarboxylase-overproducing NIH 3T3 cells induce rapidly growing, hiehly vascularized tumors in nude mice. Cancer Res 57: 3016-3025, 1997.
48. Lazaris-Karatzas A, Montine KS and Sonenberg S: Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 345: 544-547, 1990.
49. Shantz LM and Pegg AE: Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation. Cancer Res 54: 2313-2316, 1994.
50. Ashida Y, Kido J, Kinoshita F, Nishino M, Shinkai K, Akedo H and Inoue H: Putrescine-dependent invasive capacity of rat ascites hepatoma cells. Cancer Res 52: 5313-5316, 1992.
51. Bartholeyns J: Treatment of metastatic Lewis lung carcinoma with DL-α-difluoromethylornithine. Eur J Cancer Clin Oncol 19: 567-572, 1983.
52. Sunkara PS and Rosenberger AL: Antimetastatic activity of D,L-α-difluoromethyl-ornithine, an inhibitor of polyamine biosynthesis, in mice. Cancer Res 47: 933-935, 1987.
53. Seiler N, Sarhan S, Grauffel C, Jones R, Knödgen B and Moulinoux JP: Endogenous and exogenous polyamines in support of tumor growth. Cancer Res 50: 5077-5083, 1990.
54. Wallon UM, Shassetz LR, Cress AE, Bowden GT and Gerner EW: Polyamine-dependent expression of the matrix metalloproteinase matrilysin in a human colon cancer-derived cell line. Mol Carcinogl 1: 138-144, 1994.
55. Rudkin BB, Mamont PS and Seiler N: Decreased protein-synthetic activity is an early consequence of spermidine depletion in rat hepatoma tissue-culture cells. Biochem J 217: 721-741, 1984.
56. Hölttä E: Polyamine requirement for polyribosome formation and protein synthesis in human lymphocytes. In: Recent Progress in Polyamine Research. Selmeci L, Brosnan ME and Seiler N (eds). Akademiai Kiado, Budapest, pp137-150, 1985.
57. Park MH, Joe YA, Kang KR, Lee YB and Wolff EC: The polyamine-derived amino acid hypusine: its post-translational formation in eIF-5A and its role in cell proliferation. Amino Acids 10: 109-121, 1996.
58. Halmekytö M, Syrjänen K, Jänne J and Alhonen L: Enhanced papilloma formation in response to skin tumor promotion in transgenic mice overexpressing the human ornithine decarboxylase gene. Biochem Biophys Res Commun 187: 493-497, 1992.
59. Megosh L, Gilmour SK, Rosson D, Peralta Soler A, Blessing M, Sawicki JA and O'Brien TG: Increased frequency of spontaneous skin tumors in transgenic mice which overexpress ornithine decarboxylase. Cancer Res 55: 4205-4209, 1995.
60. Seiler N and Bolkenius FN: Polyamine reutilization and turnover in mouse brain. Neurochem Res 10: 529-544, 1985.
61. Sarhan S, Dezeure F and Seiler N: Putrescine derivatives as substrates of spermidine synthase. Int J Biochem 19: 1037-1047, 1987.
62. Seiler N, Sarhan S, Mamont P, Casara P and Danzin C: Some biological consequences of S-adenosylmethionine decarboxylase inhibition by MDL 73811. Life Chem Rep 9: 151-162, 1991.
63. v-src: delineation of the molecular events relevant for the transformed phenotype. J Cell Biol 122: 903-914, 1993.
64. Tabib A and Bachrach U: Polyamines induce malignant trans-formation in cultured NIH 3T3 fibroblasts. Int J Biochem Cell Biol 30: 135-146, 1998.
65. Peralta Soler A, Gilliard G, Megosh L, George K and O'Brien TG: Polyamines regulate expression of the neoplastic phenotype in mouse skin. Cancer Res 58: 1654-1659, 1998.
66. Poulin R, Lu L, Ackermann B, Bey P and Pegg AE: Mechanism of the irreversible inactivation of mouse ornithine decarboxylase by α-difluoromethylornithine. J Biol Chem 267: 150-158, 1992.
67. McCann PP, Pegg AE and Sjoerdsma A (eds): Inhibition of Polyamine Metabolism. Academic Press, Orlando, 371 pages, 1987.
68. Brachet P, Quemener V, Havouis R, Tome D and Moulinoux JP: Alterations in intestinal uptake of putrescine and tissue polyamine concentrations in tumor-bearing rats. Biochim Biophys Acta Mol Basis Dis 1227: 161-170, 1994.
69. Sunkara PS, Baylin SB and Luk GD: Inhibitors of polyamine biosynthesis: cellular and in vivo effects on tumor proliferation. In: Inhibition of Polyamine Metabolism. McCann PP, Pegg AE and Sjoerdsma A (eds). Academic Press, Orlando, pp121-140, 1987.
70. Schechter PJ, Barlow JLR and Sjoerdsma A: Clinical aspects of inhibition of ornithine decarboxylase with emphasis on therapeutic trials of Eflornithine (DFMO) in cancer and protozoan diseases. In: Inhibition of Polyamine Metabaolism. McCann PP, Pegg AE and Sjoerdsma A (eds). Academic Press, Orlando, pp345-364, 1987.
71. Levin VA, Prados MD, Yung WKA, Gleason MJ, Ictech S and Malec M: Treatment of recurrent gliomas with eflornithine. J Natl Cancer Inst 84: 1432-1437, 1992.
72. Nishioka K, Folien Mitchell M and Ajani JA: Clinical studies of polyamines and their antimetabolites. In: Polyamines and Cancer: Basic Mechanisms and Clinical Approaches. Nishioka K (ed). Springer/Landes, New York, Austin, pp251-278, 1996.
73. Moulinoux JP, Quemener V, Cipolla B, Guillé F, Havouis R, Martin C, Lobel B and Seiler N: The growth of MAT-LyLu rat prostatic adenocarcinoma can be prevented in vivo by polyamine deprivation. J Urol 146: 1408-1412, 1991.
74. Moulinoux JP, Darcel F, Quemener V, Havouis R and Seiler N: Inhibition of the growth of U-251 human glioblastoma in nude mice by polyamine deprivation. Anticancer Res 11: 175-180, 1991.
75. Hessels J, Kingma AW, Muskiet FAJ, Sarhan S and Seiler N: Growth inhibition of two solid tumors in mice, caused by polyamine depletion, is not attended by alterations in cell cycle phase distribution. Int J Cancer 48: 697-703, 1991.
76. Seiler N and Atanassov C: The natural polyamines and the immune system. In: Progress in Drug Research. Vol. 43. Jucker E (ed). Birkhauser, Basel, pp87-141, 1994.
77. Heby O, Luk GD and Schindler J: Polyamine synthesis inhibitors act as both, inducers and suppressors of cell differentiation. In: Inhibition of Polyamine Metabolism. McCann PP, Pegg AE and Sjoerdsma A (eds). Academic Press, Orlando, pp165-186, 1987.
78. Kingsnorth AN, King WWK, Diekema AK, McCann PP, Ross JS and Mal RA: Inhibition of ornithine decarboxylase with 2-difluoromethylornithine: reduced incidence of dimethylhydrazine-induced colon tumors in mice. Cancer Res 43: 2545-2549, 1983.
79. McGarrity TJ and Pfeiffer LP: Selenium and difluoromethylornithine additively inhibit DMH-induced distal colon tumor formation in rats fed a fiber-free diet. Carcinogenesis 14: 2335-2340, 1993.
80. Tsunoda A, Shibusawa M, Tsunoda Y, Yasuda N and Koike T: Reduced growth rate of dimethylhydrazine-induced colon tumors in rats. Cancer Res 52: 696-700, 1992.
81. Nigro NF, Bull AW and Boyd ME: Inhibition of intestinal carcinogenesis in rats: effect of difluoromethylornithine with piroxicam or fish oil. J Natl Cancer Inst 77: 1309-1313, 1986.
82. Reddy BS, Nayini J, Tokumo K, Rigotty J, Zang E and Keloff G: Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a non-steroidal antiinflammatory drug with D,L-α-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 50: 2562-2568, 1990.
83. Rao CV, Tokumo K, Rigotty J, Zang E, Keloff G and Reddy BS: Chemoprevention of colon cancerogenesis by dietary administration of piroxicam, α-difluoromethylornithine, 16-α-fiuoro-5-androstcn-17-one, and ellagic acid individually and in combination. Cancer Res 51: 4582-4534, 1991.
84. Liu T, Mokuolo AO, Rao CV, Reddy BS and Holt PR: Regional chemoprevention of carcinogen-induced tumors in rat colon. Gastroenterolgy 109: 1167-1172, 1995.
85. Kulkarni N, Zang E, Keloff G and Reddy BS: Effect of chemopreventive agents piroxicam and α-difluoromethylornithine on intermediate biomarkers of colon carcinogenesis. Carcinogenesis 13:995-1000, 1992.
86. Wargovich MJ, Harris C, Chen CD, Palmer C, Steele VE and Kelloff GJ: Growth kinetics and chemoprevention of aberrant crypts in the rat colon. J Cell Biochem 16G (Suppl.): 51-54, 1992.
87. Kojima T, Tanaka T, Kawamori T, Hara A and Mori H: Chemopreventive effects of dietary D,L-α-difluoromethylornithine, an ornithine decarboxylase inhibitor, on initiation and postinitiation stages of diethylnitrosamine-induced rat hepatocarcinogenesis. Cancer Res 53: 3903-3907, 1993.
88. Fozard JR and Prakash NJ: Effects of α-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, on the rat mammary tumor induced by 7,12-dimethylbenz[α]anthracene. Naunyn Schmiedebergs Arch Pharmacol 320: 72-77, 1982.
89. Ratko TA, Detrisac CJ, Rao KV, Thomas C, Keloff GJ and Moon RC: Interspecies analysis of the chemopreventive efficacy of dietary α-difluoromethylornithine. Anticancer Res 10: 67-72, 1990.
90. Thompson HJ, Herbst EJ, Meeker LD, Minocha R, Ronan AM and Fite R: Effect of D,L-α-difluoromethylornithine on murine mammary carcinogenesis. Carcinogenesis 5: 1649-1651, 1984.
91. Schedin PJ, Strange R, Singh M, Kaeck MR, Fontaine SC and Thompson HJ: Treatment with chemopreventive agents, difluoro-methylornithine and retinyl acetate, results in altered mammary extracellular matrix. Carcinogenesis 16: 1787-1794, 1995.
92. Weeks CE, Herrmann AL, Nelson FR and Slaga TJ: α-Difluoro-methylornithine, an irreversible inhibitor of ornithine decarbo-xylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin. Proc Natl Acad Sci USA 79: 6028-6032, 1982.
93. Takigawa M, Verma AK, Simsiman RC and Boutwell RK: Inhibition of mouse skin tumor promotion and of promoter-stimulated epidermal polyamine synthesis by α-difluoromethylornithine. Cancer Res 43: 3732-3738, 1983.
94. Lehnert T, Buhl K and Ivankoyic S: Inhibition of gastric tumori-genesis by α-difluoromethylornithine in rats treated with N-methyl-N-nitro-nitrosoguanidine. J Cancer Res Clin Oncol 119: 594-598, 1993.
95. Tanaka T, Kojima T, Hara A, Sawada H and Mori H: Chemoprevention of oral carcinogenesis by DL-α-difluoromethylornithine, an ornithine decarboxylase inhibitor: dose-dependent reduction in 4-nitroquino!ine 1-oxide-induced tongue neoplasm in rats. Cancer Res 53: 772-776, 1993.
96. Homma Y, Kakizoe T, Somma S and Oyasu R: Inhibition of N-butyl-N(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinocenesis by α-difluoromethylornithine. Cancer Res 47: 6176-6179, 1987.
97. Moon RC, Keloff GJ and Detrisac CJ: Chemoprevention of OH-induced bladder cancer in mice by oltipraz alone and in combination with 4-HPR and DFMO. Anticancer Res 14: 5-12, 1994.
98. Alexandrov VA, Bespalov VG, Boone CW, Keloff GJ and Malone WF: Study of postnatal effects of chemopreventive agents on offspring of ethylnitrosourea-induced transplacental carcino-genesis in rats. I. Influence of retinol acetate, α-tocopherol acetate, thiamine chloride, sodium selenite and α-difluoro-methylornithine. Cancer Lett 60: 177-184, 1991.
99. Kramer DL: Polyamine inhibitors and analogs. In: Polyamines in Cancer: Basic Mechanisms and Clinical Approaches. Nishioka K (ed). Springer/Landes, New York, Austin, pp151-189, 1996.
100. Bey P, Danzin C and Jung M: Inhibition of basic amino acid decarboxylases involved in polyamine biosynthesis. In: Inhibition of Polyamine Metabolism. McCann PP, Pegg AE and Sjoerdssma A (eds). Academic Press, Orlando, pp1-31, 1987.
101. Cornbleet MA, Kingsnorth A, Tell GP, Haegele KD, Joder-Ohlenbusch AM and Smyth JF: Phase I study of methylacetylenic putrescine, an inhibitor of polyamine biosynthesis. Cancer Chemother Pharmacol 23: 348-352, 1989.
102. Williams-Ashman HG and Seidenfeld J: Aspects of the biochemical pharmacology of methylglyoxal-bis(guanylhydrazone). Biochem Pharmacol 35: 1217-1225, 1986.
103. Stanek J, Caravatti G, Capraro HG, Furet P, Mett H, Schneider P and Regenass U: S-Adenosylmethionine decarboxylase inhibitors: new aryl and heteroaryl analogues of methylglyoxal bis(guanylhydrazone). J Med Chem 36: 46-54, 1993.
104. Regenass U, Mett H, Stanek J, Mueller M, Kramer D and Porter CW: CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity. Cancer Res 54: 3210-3217, 1994.
105. Byers TL, Wiest L, Wechter RS and Pegg AE: Effects of chronic 5′-[((Z)-4-amino-2-butenyl)methylamino]-5′-deoxyadenosine (AbeAdo) treatment on polyamine and eIF-5A metabolism in AbeAdo-sensitive and resistant L1210 murine leukemia cells. Biochem J 290: 115-121, 1993.
106. Seiler N, Delcros JG, Cipolla B, Chamaillard L, Havouis R, Quemener V and Moulinoux JP: Observations with an S-adenosylmethionine decarboxylase inhibitor in rats with prostatic adcnocarcinoma. Drug Res 46: 311-315, 1996.
107. Hcby O and Jänne J: Polyamine antimetabolites: biochemistry, specificity, and biological effects of inhibitors of polyamine synthesis. In: Polyamines in Biology and Medicine. Morris DJ and Marion LJ (eds). Marcel Dekker, New York, pp243-310, 1981.
108. Iishi II, Tatsuta M, Baba M, Uehara H and Nakaizumi A: Ornithine decarboxylase inhibitor attenuates bombesin enhancement of intestinal carcinogenesis and metastasis induced by azoxymethane. Int J Cancer 58: 533-537, 1994.
109. Iishi H, Tatsuta M, Baba M, Yano H, Sakai N, Uehara H and Nakaizumi A: Ornithinc decarboxylase inhibitor lessens the rat gastric carcinogenesis enhancement caused by tyrosine methylester. Int J Cancer 73: 113-116, 1997.
110. Tatsuta M, Iishi A, Baba M, Yano H, Uehara H and Nakaizumi A: Ornithine decarboxylase inhibitor attenuates NaCl enhancement of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine. Carcinogenesis 16: 2107-2110, 1995.
111. Tatsuta M, Iishi A, Baba M, Yamamoto R, Uehara H and Nakaizumi A: Attenuation of vasoactivc intestinal peptide enhancement of colon carcinogenesis by ornithine decarboxylase inhibitor. Cancer Lett 93: 219-225, 1995.
112. Porter CW and Sufrin J R: Interference with polyamine biosynthesis and/or function by analogs of polyamines or methionine as a potential anticancer chemotherapeutic strategy. Anticancer Res 6: 525-542, 1986.
113. Edwards ML, Prakash NJ, Stemerick DM, Sunkara PS, Bitonti AJ, Davis GF, Dumont JA and Bey P: Polyamine analogues with antitumor activity. J Med Chem 33: 1369-1375, 1990.
114. Bergeron RJ, McManis JS, Liu CZ, Feng Y, Weimar WR, Luchetta GR, Wu Q, Ortiz-Ocasio OJ, Vinson JRT, Kramer D and Porter CW: Antiproliferative properties of polyamine analogues: a structure-activity study. J Med Chem 37: 3464-3476, 1994.
115. Casero RA Jr, Mank AR, Saab NH, Wu R, Dyer WJ and Woster PM: Growth and biochemical effects of unsymmetrically substituted polyamine analogues in human lung tumor cells. Cancer Chemother Pharmacol 36: 69-74, 1995.
116. Basu HS, Pellarin M, Feuerstein BG, Shirahata A, Samejima K, Deen FE and Marton LJ: Interaction of a polyamine analogue, 1,19-bis-(ethylamino)-(5,10,15)-triazanonadecane (BE-4-4-4-4), with DNA and effect on growth, survival and polyamine levels in seven brain tumor cell lines. Cancer Res 53: 3948-3955, 1993.
117. Bergeron CJ, Basu HS, Marton LJ, Deen DF, Pellarin M and Feuerstein BG: Two polyamine analogs (BE-4-4-4 and BE-4-4-4-4) directly affect growth, survival, and cell cycle progression in two human brain tumor cell lines. Cancer Chemother Pharmacol 36: 411-417, 1995.
118. Auchter RM, Pickart MA, Nash GA and Harari PM: Growth inhibition of squamous cell carcinoma xenografts with the polyamine analogue BE 4444. Arch Otolaryngol Head Neck Surg 122: 977-981, 1996.
119. Douaud F, Le Roch N, Renault J, Havouis R, Vaultier M, Moulinoux JP and Seiler N: Dimethylsilane polyamines: cytostatic compounds with potentials as anticancer drugs. Anticancer Drug Design 12: 621-633, 1997.
120. Seiler N, Douaud F, Havouis R, Le Roch N, Renault J, Vaultier M and Moulinoux JP: Dimethylsilane polyamines, a new class of potential anticancer drugs: effects on the growth of Lewis lung carcinoma in mice. Int J Oncol 11: 835-841, 1997.
121. 12-bis(ethyl)spermine. Biochem J 291: 131-137, 1993.
122. Chang BK, Liang YY, Miller DW, Bergeron RJ, Porter CW and Wang G: Effect of diethylspermine analogs in human bladder cancer cell lines in culture. J Urol 150: 1293-1297, 1993.
123. Poulin R, Pellettier G and Pegg AE: Induction of apoptosis by excessive polyamine accumulation in ornithine decarboxylase overproducing L1210 cells. Biochem J 311: 723-727, 1995.
124. Tobias KE and Kahana C: Exposure to ornithine results in excessive accumulation of putrescine and apoptotic cell death in ornithine decarboxylase overproducing mouse myeloma cells. Cell Growth Differ 6: 1279-1285, 1995.
125. Parchment RE: An Overview of the known and suspected mechanisms for control of apoptosis by polyamines and their metabolites. In: Polyamines in Cancer: Basic Mechanisms and Clinical Approaches. Nishioka K (ed). Springer/Landes, New York, Austin, pp99-150, 1996.
126. Kramer DL, Fogel-Petrovic M, Diegelman P, Cooley JM, Bernacki RJ, McManis JS, Bergeron RJ and Porter CW: Effects of novel spermine analogues on cell cycle progression and apoptosis in MALME-3M human melanoma cells. Cancer Res 57: 5521-5527, 1997.
127. McCloskey DE, Casero RA Jr, Woster PM and Davidson NE: Induction of programmed cell death in human breast cancer cells by an unsymmetrically substituted polyamine analogue. Cancer Res 55: 3233-3236, 1995.
128. Ha HC, Woster PM, Yager JD and Casero RA Jr: The role of polyamine catabolism in polyamine analogue-induced programmed cell death. Proc Natl Acad Sci USA 94: 11557-11562, 1997.
129. Bates S and Vousden KH: p53 in signalling check point arrest orapoptosis. Curr Opin Genet Dev 6: 12-19, 1996.
130. Mortensen PB: Neuroleptic treatment and other factors modifying cancer risk in schizophrenic patients. Acta Psychiatr Scand 75: 585-590, 1987.
131. Mortensen PB: Neuroleptic medication and reduced risk of prostate cancer in schizophrenic patients. Acta Psychiatr Scand 85: 390-393, 1992.
132. Johnson JD and Mills JS: Calmodulin. Mcd Res Rev 6: 341-363, 1986.
133. McManus JP, Boynton AL and Whitfield JF: Cyclic AMP and calcium as intracycle regulators in the control of cell proliferation. Adv Cyclic Nucleotide Res 9: 485-491, 1978.
134. Martin RL, Ilett KF and Minchin RF: Cell cycle-dependent uptake of putrescine and its importance in regulating cell cycle transition in cultured adult hepatocytes. Hepatology 14: 1243-1250, 1991.
135. DeBenedetto M, Olson JW and Snow EC: Expression of polyamine transporter activity during B lymphocyte cell cycle progression. J Immunol 150: 4218-4224, 1993.
136. Ginty DD and Seidel ER: Polyamine-dependent growth and calmodulin-regulated induction of ornithine decarboxylase. Am J Physiol 256: G342-G348, 1989.
137. Seiler N, Douaud F, Renault J, Delcros JG, Havouis R, Uriac P and Moulinoux JP: Polyamine sulfonamides with NMDA antagonist properties are potent calmodulin antagonists and cytotoxic agents. Int J Biochem Cell Biol 30: 393-406, 1998.
138. Heston WDW and Charles M: Calmodulin antagonists inhibition of polyamine transport in prostatic cancer cells in vitro. Biochem Pharmacol 37: 2511-2514, 1988.
139. 2+-ATPase. J Cell Physiol 157: 493-501, 1993.
140. Scemama JL, Grabie V and Seidel E: Characterization of univectorial polyamine transport in duodenal crypt cell line. Am J Physiol 265: G851-G856, 1994.
141. Dumontier AM, Brachet P, Huneau JF and Tome D: Transport of putrescine in the isolated rabbit intestine. Pflügers Arch Pharmacol 420: 329-335, 1992.
142. Tatsuta M, Iishi H, Baba M, Yano H, Uehara H, Nakaizumi A and Iseki K: Inhibition by the calmodulin antagonist trifluoperazine of experimental hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats. Cancer Lett 107: 179-185, 1996.
143. Soriano M, Pinol R, Enrich C and Bachs O: Effect of trifluoperazine on DNA synthesis during liver regeneration. Cell Tissue Kinet 18: 475-481, 1995.
144. Alexander RW, Saydjari R, MacLellan DG, Townsend CM Jr and Thompson JC: Calmodulin antagonist trifluoperazine inhibits polyamine biosynthesis and liver regeneration. Br J Surg 75: 1160-1162, 1988.
145. Hidaka H, Sassaki T, Tanaka T, Ohno S, Fuji Y and Nagata T: N-(6-Aminohexyl)-5-chloro-1-naphthalene sulfonamide a calmodulin antagonist inhibits cell proliferation. Proc Natl Acad Sci USA 78: 4354-4357, 1991.
146. Xiong A and Shen H: Effect of calmodulin antagonist on chemosensitivity of primary cultured lung cancer cells. Chung Hua Chung Liu Tsa Chih 17: 347-349, 1995.
147. Tanaka M, Wayda K, Molnar J and Motohashi N: Antimutagenicity of benzo[a]phenothiazines in chemically induced mutagenesis. Anticancer Res 16: 3625-3628, 1996.
148. Ghosh N and Chattopadhyay U: Enhancement of immune response by phenothiazine administration in vivo. In Vivo 7: 435-440, 1993.
149. Frankfurt OS, Sugarbaker EV, Robb JA and Villa L: Synergistic induction of apoptosis in breast cancer cells by tamoxifen and calmodulin inhibitors. Cancer Lett 97: 149-154, 1995.
150. Dewhurst LO, Gee JW, Rennie IG and MacNeil S: Tamoxifen, 17-ß-oestradiol and the calmodulin antagonist J8 inhibit human melanoma cell invasion throueh fibronectin. Br J Cancer 75: 860-868, 1997.
151. Stoner GD and Mukhtar H: Polyphenols as cancer chemopreventive agents. J Cell Biochem 22 (Suppl.): 169-280, 1995.
152. Gali HU, Perchellet EM and Perchellet JP: Inhibition of tumor promoter-induced ornithine decarboxylase activity by tannic acid and other polyphenols in mouse epidermis in vivo. Cancer Res 51: 2820-2825, 1991.
153. Agarwal R, Katiyar SK, Zaidi SLA and Mukhtar H: Inhibition of skin tumor promoter-caused induction of epidermal ornithine decarboxylase in SENCAR mice by polyphenolic fraction isolated from green tea and its individual epicatechin derivatives. Cancer Res 52: 3582-3588, 1992.
154. Gerhäuser C, Mar W, Lee SK, Suh N, Luo Y, Kosmeder J, Luyengi L, Fong HH, Kinghorn AD, Moriarty RM, Mehta RG, Constantinou A, Moon RC and Pezzuto JM: Rotenoids mediate potent cancer chemopreventive activity through transcriptional regulation of ornithine decarboxylase. Nat Med 1: 260-266, 1995.
155. Hu G, Han C and Chen J: Inhibition of oncogene expression by green tea and (-)-epigallocatechin gallate in mice. Nutr Cancer 24: 203-209, 1995.
156. Rao CV, Simi B and Reddy BS: Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis 14: 2219-2225, 1993.
157. Zheng ZS, Xue GZ, Grunberger D and Prystowsky JH: Caffeic acid phenylester inhibits proliferation of human keratinocytes and interferes with the EGF regulation of ornithine decarboxylase. Oncol Res 7: 445-452, 1995.
158. Achiwa Y, Hibasami H, Katsuzaki H, Imai K and Kosmiya T: Inhibitory effects of persimmon (Diospyros kaki) extract and related polyphenol compounds on human lymphoid leukemia cells. Biosci Biotechnol Biochem 61: 1099-1101, 1997.
159. Alberts DS and Garcia DJ: An overview of clinical cancer chemoprevention studies with emphasis on positive phase III studies. J Nutr 125 (Suppl. 3): 692S-697S.
160. Lippman SM, Heyman RA, Kurie JM, Benner SE and Hong WK: Retinoids and chemoprevention: clinical and basic studies. J Cell Biochem 22: 1-10, 1995.
161. Keloff GJ, Boone CW, Crowell JA, Steele VE, Lubet RA, Doody LA, Malone WF, Hawk ET and Sigman CC: New agents for cancer chemoprevention. J Cell Biochem 26 (Suppl.): 1-28, 1996.
162. Giacosa A, Filiberti R, Hill MJ and Faivre J: Vitamins and cancer chemoprevention. Eur J Cancer Prev 6 (Suppl. I): S47-S54, 1997.
163. Kurlandsky SB, Xiao JH, Duell EA, Vorhees JJ and Fisher GJ: Biological activity of all-trans retinol requires metabolic conversion to all-trans retinoic acid and is mediated through activation of nuclear retinoid receptors in human keratinocytes. J Biol Chem 269: 32821-32827, 1994.
164. Giannini F, Maestro R, Vukosavljevic T, Pomponi F and Boiocchi M: All-trans, 13-cis and 9-cis retinoic acids induce a fully reversible growth inhibition in HNSCC cell lines: implications for in vivo retinoic acid use. Int J Cancer 70: 194-200, 1997.
165. Elitsur Y, Neace C, Liu X, Donescu J and Moshier JA: Vitamine A and retinoic acid immunomodulation on human gut lymphocytes. Immunopharmacology 35: 247-253, 1997.
166. Ross AC and Ternus ME: Vitamine A as a hormone: recent advances in understanding the actions of retinol, retinoic acid and ß-carotene. J Am Diet Assoc 93: 1285-1290, 1993.
167. Langenfeld J, Kiyokawa H, Sekula D, Boyle J and Dimitrovsky E: Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanisms. Proc Natl Acad Sci USA 94: 12070-12074, 1997.
168. Mao Y, Gurr JA and Hickock NJ: Retinoic acid regulates ornithine decarboxylase gene expression at the transcriptional level. Biochem J 295: 641-644, 1993.
169. Zheng ZS, Xue GZ and Prystowsky JH: Regulation of the induction of ornithine decarboxylase in keratinocytes by retinoids. Biochem J 309: 156-159, 1995.
170. Verma AK and Boutwell RK: Inhibition of tumour promoterinduced mouse epidermal ornithine decarboxylase activity and prevention of skin carcinogenesis by vitamin A acid and its analogues (retinoids). In: Polyamines in Biomedical Research. Gaugas JM (ed). Wiley, Chichester, pp185-253, 1980.
171. Moon TE, Levine N, Cartmel B and Bangert JL: Retinoids in prevention of skin cancer. Cancer Lett 114: 203-205, 1997.
172. Tan A, Wu K and Huang M: Inhibition of ornithine decarboxylase activity and epidermal papilloma in mice by ß-carotene. Chung Hua Yu Fang I Hsueh Tsa Chih 29: 360-362, 1995.
173. Meyskens FL Jr, Kingsley EM, Glattke T, Loescher L and Booth A: A phase II study of α-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma. Invest New Drugs 4: 257-262, 1986.
174. Warrell RP Jr, Coonley CJ and Burchenal JH: Sequential inhibition of polyaminc synthesis. A phase I trial of DFMO (α-difluoromethylornithine) and methyl-GAG [methylglyoxal-bis (guanylhydrazone)]. Cancer Chemother Pharmacol 11: 134-136, 1983.
175. Barrett JT, Orofiamma B, Khandekar ID, Carbone PP, Comis RL and Davis TE: A phase II study of mitoguazone and vinblastine in advanced transitional cell carcinoma of the urinary tract. Cancer 64: 2445-2447, 1989.
176. Sordillo PP, Magill GB and Welt S: Phase II trial of methylglyoxal-bis-guanylhydrazone (methyl-GAG) in patients with soft-tissue sarcomas. Am J Clin Oncol 8: 316-318, 1985.
177. Winter JN, Ritch PS, Rosen ST, Oken MM, Wolter JM, Wiernik PH and O'Connell MJ: Phase II trial of methylglyoxal-bis(guanylhydrazone) (MGBG) in patients with refractory multiple myeloma: an Eastern Cooperative Oncology group (ECOG) study. Cancer Invest 8: 143-146, 1990.
178. Keloff GJ, Crowell JA, Boone CW, Steele VE, Lubet RA, Greenwald P, Alberts DS, Covey JM, Doody LA and Knapp GG: Strategy and planning for chcmopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute. J Cell Biochem 20 (Suppl.): 55-62, 1994.
179. Keloff GJ, Boone CW, Crowell JA, Nayfield SG, Hawk E, Steele VE, Lubet RA and Sigman CC: Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary. J Cell Biochem 23 (Suppl.): 1-9, 1995.
180. Keloff GJ, Crowell JA, Boone CW, Steele VE, Lubet RA, Grenwald P, Alberts DS, Covey JM, Doody LA and Knapp GG: Clinical development plan: 2-difluoromethylornithine (DFMO). J Cell Biochem 20 (Suppl.): 147-165, 1994.
181. Mi Z, Kramer DL, Bergeron RJ, Bernacki R and Porter CW: Human prostate carcinoma cell lines display altered regulation of polyamine transport in response to polyamine analogs and inhibitors. Prostate 34: 51-60, 1998.
182. Einspahr JG, Alberts DS, Gapstur SM, Bostick RM, Emerson SS and Gerner EW: Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials. Cancer Epidemiol Biomarkers Prev 6: 37-48, 1997.
183. Schatzkin A and Kcloff G: Chemo- and dietary prevention of colorectal cancer. Eur J Cancer 31A: 1198-1204, 1995.
184. Abeloff MD, Rosen ST, Luk GD, Baylin SB, Zeltzman M and Sjoerdsma A: Phase II trials of α-difluoromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer. Cancer Treat Rep 70: 843-845, 1986.
185. Pendyala L, Creavan PJ and Porter CW: Urinary and erythrocyte polyamines during the evaluation of oral α-difluoromethylornithine in a phase I chemoprevention clinical trial. Cancer Epidemiol Biomarkers Prev 2: 235-241, 1993.
186. Boiko IV, Mitchell MF, Pandley DK, White RA, Hu W, Malpica A, Nishioka K, Boone CW, Atkinson EN and Hittelman WN: DNA image cytometric measurement as a surrogate end-point biomarker in a phase I trial of α-difluoromethylornithine for cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 6: 849-955, 1997.
187. Mitehell MF, Hittelman WK, Lotan R, Nishioka K, Tortolero-Luna G, Richards-Kortum R, Wharton JT and Hong WK: Chemoprevention trials and surrogate end-point biomarkers in the cervix. Cancer 76 (Suppl. 10): 1956-1977, 1995.
188. Loprinzi CL and Messing EM: A prospective clinical trial of difluoromethylornithine (DFMO) in patients with resected superficial bladder cancer. J Cell Biochem 161 (Suppl.): 153-155, 1992.
189. Garewal HS, Samplincr RE and Fennerty MB: Chemopreventive studies in Barrett's esophagus: a model prcmalignant lesion for esophageal adenocarcinoma. J Natl Cancer Inst Monogr 13: 51-54, 1992.
190. Crowell JA, Goldenthal EI, Keloff GJ, Malone WF and Boone CW: Chronic toxicity studies of the potential cancer preventive 2-(difluoromcthyl)-dl-ornithine. Fundam Appl Toxicol 22: 341-354, 1994.
191. Horn Y, Schechter PJ and Marion LJ: Phase I-II clinical trial with α-difluoromethylornithine - an inhibitor of polyamine biosynthesis. Eur J Cancer Clin Oncol 23: 1103-1107, 1987.
192. Pasic TR, Heisey D and Love RR: α-Difluoromethylornithine ototoxicity. Chemoprevention clinical trial results. Arch Otolaryngol Head Neck Surg 123: 1281-1286, 1997.
193. Creavan PJ, Pendyala L and Peterli NJ: Evaluation of α-difluoromethylornithine as a potential chemopreventive agent: tolerance to daily oral administration in humans. Cancer Epidemiol Biomarkers Prev 2: 243-246, 1993.
194. Love RR, Carbone PP, Verma AK, Gilmore D, Carey P, Tutsch KD, Pompleen M and Wilding G: Randomized phase I chemoprevention dose-seeking study of α-difluoromethyl-ornithine. J Natl Cancer Inst 85: 732-737, 1993.
195. McConlogue L and Coffino P: A mouse lymphoma cell mutant whose major protein product is ornithine decarboxylase. J Biol Chem 258: 12083-12086, 1983.
196. Alhonen-Hongisto L, Kallio A, Sinervirta L, Seppänen P, Kontula KK, Jänne OA and Janne J: Difluoromethylornithine-induced amplification of ornithine decarboxylase genes in Ehrlich ascites carcinoma cells. Biochem Biophys Res Commun 126: 734-740, 1985.
197. Kahana C and Nathans D: Translational regulation of mammalian ornithine decarboxylase by polyamines. J Biol Chem 260: 15390-15393, 1985.
198. Mitchell JL, Hoff JA and Bareyal-Leyser A: Stable ornithine decarboxylase in a rat hepatoma cell line selected for resistance to α-difluoromethylomithine. Arch Biochem Biophys 290: 143-152, 1991.
199. Bardocz S: Polyamines in tissue regeneration. In: The Physiology of Polyamines. Vol. 1. Bachrach U and Heimer YM (eds). CRC Press, Boca Raton, pp95-106, 1989.
200. Luk GD, Marion LJ and Baylin SB: Ornithinc decarboxylase is important in intestinal mucosal maturation and recovery from injury in rats. Science 210: 195-188, 1980.
201. Kummerlen C, Seiler N, Galluser M, Gossé F, Knödgen B, Hasselmann M and Raul F: Polyamines and the recovery of intestinal morphology and function after ischemic damage in rats. Digestion 55: 168-174, 1994.
202. Fozard JR, Part ML, Prakash NJ, Grove J, Schlechter PJ, Sjoerdsma A and Koch-Weser J: L-Ornithine decarboxylase: an essential role in early mammalian embryogenesis. Science 208: 505-508, 1980.